Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus

被引:51
作者
Gaubitz, M
Seidel, M
Kummer, S
Schotte, H
Perniok, A
Domschke, W
Schneider, M
机构
[1] Univ Munster, Dept Rheumatol, Med Clin B, D-48129 Munster, Germany
[2] Univ Dusseldorf, D-4000 Dusseldorf, Germany
关键词
extracorporeal treatment; immunoadsorption; systemic lupus erythematosus;
D O I
10.1006/jaut.1998.0229
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Experiences with extracorporeal therapy in systemic lupus erythematosus have been published over the last 20 years and more. In addition to plasmapheresis, specific adsorption columns have been developed to deplete pathogenic antibodies and immune complexes in the plasma of patients with SLE. We conducted a prospective randomized trial to compare the efficacy of a disposable adsorption column, which contained a specific ligand, phenylalanine (IMPH-350(TM) Diamed, Koln, Germany) with a regenerable Ig-adsorbing column containing sheep anti-human antibodies (Ig-Therasorb(TM) Therasorb, Munchen, Germany). Twenty SLE patients inadequately controlled with corticosteroids, anti-malarials, azathioprine or cyclosporine A, had strong evidence of disease in general, or an organ related SLAM score. They were randomized to receive either a perfusion of IMPH-350, or Ig-Therasorb, immunoadsorbed with 2.5 ml of plasma, three times each. The treatment regime was repeated after 4 weeks when the response was limited or non-existent. Response was defined as a reduction in the SLAM score of at least 30%. SLAM scores in the IMPH group decreased from 14.3+/-5.6 to 9.2+/-6.2 after 1 month and to 9.4+/-3.9 after 6 months; corresponding scores in the Ig-Therasorb group were 18.3+/-5.5 to 11.2+/-7.6, decreasing to 9.2+/-2.9. After 1, month, 8/10 patients in bath groups showed a response; after 6 months, 5/10 patients in the IMPH-350 group and 8/10 in the Ig-Therasorb group fulfilled the response criteria. Reduction of dsDNA antibodies directly after treatment was 50.8+/-6.6% in the IMPH-350 group and 61.0+/-8.0% in the IgTherasorb group. Results indicate that irmnunoadsorption is an additional option in the treatment of severe SLE. Choice of type of immunoadsorber and immunosuppressive treatment has to take into account the severity and chronicity of common disease activity and organ involvement, as well as economic aspects. (C) 1998 Academic Press
引用
收藏
页码:495 / 501
页数:7
相关论文
共 25 条
  • [1] Aringer M, 1998, ARTHRITIS RHEUM, V41, P414, DOI 10.1002/1529-0131(199803)41:3<414::AID-ART6>3.0.CO
  • [2] 2-N
  • [3] BARR WG, 1987, 1ST P INT C WORLD AP, V6, P696
  • [4] ANTIBODY-BASED IMMUNOADSORPTION AS A THERAPEUTIC MEANS
    DUMOULIN, A
    MULLERDERLICH, J
    BIEBER, F
    RICHTER, WO
    FREI, U
    MULLER, R
    SPAETHE, R
    [J]. BLOOD PURIFICATION, 1993, 11 (03) : 145 - 149
  • [5] TREATMENT-FREE REMISSION IN SEVERE SYSTEMIC LUPUS-ERYTHEMATOSUS FOLLOWING SYNCHRONIZATION OF PLASMAPHERESIS WITH SUBSEQUENT PULSE CYCLOPHOSPHAMIDE
    EULER, HH
    SCHROEDER, JO
    HARTEN, P
    ZEUNER, RA
    GUTSCHMIDT, HJ
    [J]. ARTHRITIS AND RHEUMATISM, 1994, 37 (12): : 1784 - 1794
  • [6] ANTIBODY DEPLETION AND CYTOTOXIC DRUG-THERAPY IN SEVERE SYSTEMIC LUPUS-ERYTHEMATOSUS
    EULER, HH
    SCHROEDER, JO
    [J]. TRANSFUSION SCIENCE, 1992, 13 (02): : 167 - 184
  • [7] HASHIMOTO H, 1991, J RHEUMATOL, V18, P545
  • [8] IDIOTYPES AND AUTOIMMUNITY - A REVIEW OF THEIR ROLE IN HUMAN-DISEASE
    HORSFALL, AC
    ISENBERG, DA
    [J]. JOURNAL OF AUTOIMMUNITY, 1988, 1 (01) : 7 - 30
  • [9] JONES JV, 1976, LANCET, V1, P709
  • [10] KOFFLER D, 1971, J EXP MED, V134, pS19